Gilead Sciences agreed to acquire German biotech Tubulis for $3.15 billion upfront plus up to $1.85 billion in milestones, totaling potentially $5 billion.123
The deal bolsters Gilead's oncology antibody-drug conjugate (ADC) pipeline, adding Tubulis' lead candidate TUB-040 (NaPi2b-directed TOPO1i ADC) in Phase 1b/2 for platinum-resistant ovarian cancer and NSCLC.123
Tubulis' TUB-030, a 5T4-targeted ADC, showed promising early data in solid tumors.23
This is Gilead's third acquisition since late February 2026, following Arcellx ($7.8B) and Ouro Medicines ($1.67B).12
Tubulis will operate as a dedicated ADC research hub in Munich within Gilead.123
Prior 2024 collaboration:
Gilead paid $20M upfront and up to $415M milestones for Tubulis' ADC platform access.1
Sources:
1. https://www.fiercebiotech.com/biotech/gilead-inks-5b-tubulis-buyout-bolster-oncology-adc-pipeline
2. https://www.biopharmadive.com/news/gilead-tubulis-acquire-deal-adc-cancer/816823/
3. https://www.finanznachrichten.de/nachrichten-2026-04/68136839-gilead-sciences-to-acquire-germany-s-tubulis-for-up-to-dollar-5-bln-020.htm